Company intelligence

SUPN

Supernus Pharmaceuticals, Inc. · NASDAQ · Healthcare

Price$45.36+0.55% · +$0.25

Market cap2.63BEquity value

P / E14.8Trailing ratio

Volume496.06KLatest session

Market data

SUPN price chart

TradingView

Related signals

1 min delayed

Browse public SUPN signals with their source context and measured market impact. Open any signal for its permanent analysis page.

SUPNFeb 19, 2025+1.74% since signal

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Phase 2b study of SPN-820 failed to meet primary endpoint for depression. No significant difference between SPN-820 and placebo was found. Safety profile for SPN-820 remains consistent with past trials. Onapgo injection approved, set for market in Q2 2025. SUPN stock down 14.10% following trial results.

View signal analysis

SUPNSep 11, 2024-1.12% since signal

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Piper Sandler downgraded SUPN to Neutral, citing unmet Qelbree prescription growth. Qelbree sales grew 92% YoY but long-term growth assumptions are re-evaluated. Peak sales projections for Qelbree adjusted from $500M to $400M. FDA granted resubmission of SPN-830’s NDA, with PDUFA date set for Feb 2025. SUPN stock fell 7.17%, reflecting market reactions to the downgrade.

View signal analysis

Research